Vanda Pharmaceuticals (STU:VM4) Gross Loan

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:VM4 Vanda Pharmaceuticals Inc STU:VM4
68 GF Score
Price €4.44
GF Value €4.81
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Vanda Pharmaceuticals Gross Loan?

Gross Loan only applies to banks.

STU:VM4
68GF Score
Vanda Pharmaceuticals Inc STU:VM4
Gross Loan is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Vanda Pharmaceuticals (STU:VM4) Overvalued in 2026?

Based on GuruFocus' analysis, Vanda Pharmaceuticals stock appears to be undervalued. The current stock price of €4.44 is trading 7.6% below its estimated GF Value™ of €4.81. GuruFocus considers Vanda Pharmaceuticals to be Fairly Valued.

Key valuation signals for STU:VM4:

  • Gross Loan:
  • GF Value™: €4.81 vs. price of €4.44 (7.6% below fair value)
  • GF Score™: 68/100 with 4 warning signs

No single metric tells the full story. See the STU:VM4 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Vanda Pharmaceuticals Business Description

Other Exchanges VNDA:USA0LKB:UK
Address 2200 Pennsylvania Avenue North West, Suite 300 E, Washington, DC, USA, 20037
Vanda Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company based in Washington, D.C., focused on developing and commercializing therapies for central nervous system disorders and other unmet medical needs. Its commercial portfolio includes HETLIOZ (tasimelteon) for Non-24-Hour Sleep-Wake Disorder and nighttime sleep disturbances in Smith-Magenis Syndrome; Fanapt (iloperidone), an antipsychotic for schizophrenia and bipolar I disorder; and PONVORY (ponesimod) for relapsing forms of multiple sclerosis. The company also advances a pipeline of investigational candidates, including tradipitant, VQW-765, and VTR-297. Vanda generates revenue primarily through product sales, with the United States as its largest market, supplemented by sales in Israel, Europe, and Canada. It also pursues licensing and collaboration arrangements, and has engaged in litigation to defend its intellectual property. Fanapt and HETLIOZ account for the majority of its revenue.
68GF Score

Get the complete analysis for STU:VM4

Gross Loan is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.44
Price
€4.81
GF Value